The genomic landscape of children with acute myeloid leukemia (AML) who do not carry any cytogenetic abnormality (CN-AML) is particularly heterogeneous and challenging, being characterized by different clinical outcomes. To provide new genetic insights into this AML subset, we analyzed through RNA-seq 13 pediatric CN-AML cases, corroborating our findings in an independent cohort of 168 AML patients enrolled in the AIEOP AML 2002/01 study. We identified a chimeric transcript involving NUP98 and PHF23, resulting from a cryptic t(11;17)(p15;p13) translocation, demonstrating, for the first time, that NUP98-PHF23 is a novel recurrent (2.6 %) abnormality in pediatric CN-AML.
Findings
Childhood acute myeloid leukemia (AML) is a heterogeneous disease with current survival rates of approximately 60-70 %. Cytogenetics, recurrent molecular abnormalities, and early response to treatment are the main factors influencing outcome [1] . However, around 20 % of pediatric AML do not carry any known cytogenetic abnormality (cytogenetically normal-AML or CN-AML). In order to shed light on this subgroup we performed wholetranscriptome sequencing (WTS) in 13 pediatric CN-AML cases, corroborating relevant findings in an independent cohort of 168 cases.
Sequencing was performed on a HiScanSQ sequencer (Illumina), and bioinformatic analysis was performed as previously described [2] . In 2 (CN-AML_54, CN-AML_66) out of 13 cases analyzed, we identified a chimeric transcript involving nucleoporin 98 kDa (NUP98) and PHD finger protein 23 (PHF23) genes, resulting from a cryptic translocation t(11;17)(p15;p13) ( Fig. 1a and Table 1 ). In both cases, we identified an in-frame fusion between NUP98 exon 13 and PHF23 exon 4 (Fig. 1b) . To date, the cryptic translocation t(11;17)(p15;p13) has been described only once in an adult AML patient [3] , but never in a pediatric AML cohort. Different from what was previously reported by Reader and colleagues [3] , in this study the recurrent breakpoint in PHF23 was always identified at the beginning of exon 4 and not within it ( Fig. 1a and b) .
To assess the incidence of NUP98-PHF23 fusion in pediatric CN-AML, we examined through RT-PCR analysis and Sanger sequencing a validation cohort of 168 AML children enrolled in the AIEOP AML 2002/01 study [4] ; one-hundred thirty-nine patients (76 males and 63 females, median age at diagnosis 7.7 years, range 17 days to 17.9 years) were negative for known recurrent genetic abnormalities involving MLL, CBFB, and FLT3, while the remaining 29 patients (15 males and 14 females, median age at diagnosis 11.8 years, range 3 to 17.4 years) harbored internal tandem duplication of FLT3 (FLT3-ITD), this latter abnormality being chosen because we previously reported a strong association between NUP98-NSD1 rearrangement and FLT3-ITD [5] . With the exception of FAB M3 (acute promyelocytic leukemia), all the FAB types were represented in the validation cohort. RNA was extracted from fresh bone marrow at diagnosis, and multiplex RT-PCR was used. Sequencing by Sanger method was applied to all cases positive by PCR to NUP98-PHF23 fusion gene. Overall, 2 out of 139 CN-AML cases were found to harbor NUP98-PHF23 (Table 1) . NUP98-PHF23 was not found in any patient harboring FLT3-ITD. Fluorescence in-situ hybridization confirmed the cryptic chromosomal translocation t(7;11)(p15;p13) leading to the fusion between NUP98 and PHF23 in all cases (Fig. 1c) .
So far, many NUP98-rearrangements have been found to be associated with both de novo and therapy-related AML but also with T-cell acute lymphoblastic leukemia with over 28 different partner genes [6] . Recently, the fusion NUP98-JARID1A has been described to be a recurrent event in pediatric acute megakaryoblastic leukemia (11 %), with a distinct HOX gene-expression pattern [7] .
Conversely, chromosomal rearrangements and/or mutations of PHF23 have never been previously described in children with AML. Located on the reverse strand of 17p13.1, PHF23 encodes for a protein containing a plant homeodomain (PHD) finger [8] involved in chromatin remodeling [3] . Expression of NUP98-PHF23 has been demonstrated to impair the differentiation of myeloid progenitor cells and promote leukemia development in vitro c FISH analysis was performed on metaphases and interphase cells using three BlueFISH probes (BlueGnome Ltd., Cambridge), according to the manufacturer's instructions. BAC clones RP11-120E20 and RP11-348A20 (red) were used to probe the NUP98 gene on chromosome 11, while the BAC clone RP11-542C16 (green) was used to target the PHF23 gene on chromosome 17. Normal metaphases (upper left) and interphase nuclei (upper right) showed two red signals representing normal copies of NUP98 and two green signals representing normal copies of PHF23. Abnormal metaphases (lower left) and interphase cells (lower right) containing the NUP98-PHF23 fusion gene showed one red (NUP98), one green (PHF23) and one yellow fusion signal, which represents the juxtaposition of the translocated portions of the two genes and in vivo [8] [9] [10] . Cells expressing NUP98-PHF23 are sensitive to disulfiram, an FDA-approved drug, demonstrating the feasibility of targeting this oncoprotein [9] . In summary, we identified, for the first time in childhood AML, a NUP98-PHF23 fusion, demonstrating that this genomic aberrancy is not exceptional (tentative frequency of 2.6 %) in pediatric CN-AML. These findings enforce the role of epigenetic regulators in pediatric AML and suggest novel therapeutic targets for this disease. 
